Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00889902|
Recruitment Status : Unknown
Verified April 2009 by Wuhan University.
Recruitment status was: Not yet recruiting
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
The purpose of this study is to:
- make p16INK4A as a cervical cancer screening of tumor markers, cytology improve existing diagnostic sensitivity, specificity, repeatability and validity, so as to effectively prompted the early discovery and diagnosis of cervical cancer.
- reduce screening costs, screening and benefits into quantitative evaluation, for our country to develop cervical cancer prevention and control strategy to provide a reliable theoretical basis.
|Condition or disease|
- To carry out large-scale prospective randomized controlled clinical study to evaluate the "cytological molecular markers Detect + P16INK4A" methods of screening accuracy and reliability, as well as the screening method of the biological effects.
- Markov set up mathematical model of screening tests to quantify the inputs and the evaluation proceeds. With a view to optimize and perfect a simple, convenient, practical and efficient program of cervical cancer screening.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis|
|Study Start Date :||April 2009|
|Estimated Primary Completion Date :||June 2010|
|Estimated Study Completion Date :||July 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889902
|Contact: Hong B Cai, Doctor||0086-027-67813044||Chb2105@163.com|
|Contact: Ying J Huang|
|Wufeng county, Hubei, China|
|Study Director:||Hong B Cai, Doctor||gynecologic oncology department, Zhongnan Hospital of Wuhan University|